Pemvidutide
Also known as: ALT-801, GLP-1/glucagon dual agonist
Pemvidutide (also called ALT-801 or GLP-1/glucagon dual agonist) is a glucagon agonist in the GLP-1 Agonist class. Pemvidutide is a dual agonist at the GLP-1 and glucagon receptors with a deliberately weighted ratio favouring glucagon activity relative to other agents in the class.
For research use only.
Key Facts
- CAS
- 2538014-94-5
- Molecular Weight (MW)
- ≈4094 g/mol
- Half-life
- ~110 hours (EuPort™ albumin-binding domain; weekly dosing)
- FDA status
- Investigational New Drug (IND)
- Administration Route
- Subcutaneous
- Frequency
- Weekly
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GLP-1 receptorGlucagon receptor
Research summary
Investigational dual agonist at the GLP-1 and glucagon receptors from Altimmune, weighted toward glucagon activity relative to others in its class. It is in development for obesity and for metabolic dysfunction-associated steatohepatitis, where reducing hepatic fat is the therapeutic target. Not FDA-approved, and efficacy and safety remain under investigation.
Peptide Library's Pemvidutide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Investigational - dosage under evaluation in clinical trials
- Frequency
- Weekly
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Investigational - not yet established
- Injection Sites
- AbdomenThighUpper arm
- Concentration Example
- Investigational - not yet established
- Timing Notes
- Investigational; follow trial schedule
- Expected Onset
- Investigational - onset under evaluation
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Pemvidutide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C182H275N39O54 |
|---|---|
| Molecular weight | ≈4094 g/mol |
| CAS number | 2538014-94-5 |
| Half-life | ~110 hours (EuPort™ albumin-binding domain; weekly dosing) |
| Appearance | Lyophilized powder or solution for sc use (investigational) |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Pemvidutide is a dual agonist at the GLP-1 and glucagon receptors with a deliberately weighted ratio favouring glucagon activity relative to other agents in the class. GLP-1 receptor activation reduces food intake through hypothalamic and brainstem circuits, while glucagon receptor activation increases hepatic energy expenditure and drives fatty-acid oxidation in the liver. That emphasis is the rationale for its investigation in metabolic dysfunction-associated steatohepatitis, where reducing hepatic lipid is the therapeutic target, as well as in obesity. It is investigational and not approved for any indication.
Origin
Synthetic peptide dual agonist.
Targets
Studies
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
- Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial
Regulatory & research status
Pemvidutide has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
Benefits
Pemvidutide side effects
Side Effects
- Nausea
- Vomiting
- Heart-rate increase possible
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Pemvidutide: frequently asked questions
What is Pemvidutide?
Investigational dual agonist at the GLP-1 and glucagon receptors from Altimmune, weighted toward glucagon activity relative to others in its class. It is in development for obesity and for metabolic dysfunction-associated steatohepatitis, where reducing hepatic fat is the therapeutic target. Not FDA-approved, and efficacy and safety remain under investigation.
How does Pemvidutide work?
Pemvidutide is a dual agonist at the GLP-1 and glucagon receptors with a deliberately weighted ratio favouring glucagon activity relative to other agents in the class. GLP-1 receptor activation reduces food intake through hypothalamic and brainstem circuits, while glucagon receptor activation increases hepatic energy expenditure and drives fatty-acid oxidation in the liver.
Is Pemvidutide FDA approved?
No. Pemvidutide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the half-life of Pemvidutide?
Reported half-life for Pemvidutide is ~110 hours (EuPort™ albumin-binding domain; weekly dosing). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Pemvidutide banned in sport?
Pemvidutide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Pemvidutide?
Compounds most often compared with Pemvidutide include Retatrutide, Survodutide, Cotadutide and Mazdutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials — Naunyn Schmiedebergs Arch Pharmacol, 2026External reference
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study — J Hepatol, 2025External reference
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study — Lancet, 2025External reference
- Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies — Clin Cancer Res, 2011External reference
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial — Lancet, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Pemvidutide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Pemvidutide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →